Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
590 Results for "
Cell viability
" in MedChemExpress (MCE) Product Catalog:
Products (590)
590 Results for "Cell viability" in MCE Product Catalog:
Cat. No.: HY-P11766A
Synonyms: GALA-cholesterol TFA
Target:
Research Areas:
GALA-chol TFA (GALA-cholesterol TFA) is a cholesterol-conjugated pH-responsive fusion peptide that can serve as a delivery adjuvant. GALA-chol TFA enhances the endocytosis of siRNA RET/PTC1-SQ nanoparticles, inhibits cell viability, and undergoes pH-responsive charge conversion in the acidic lysosomal environment, thereby promoting lysosomal escape of small extracellular vesicle (sEV) cargo. GALA-chol TFA anchors to the sEV membrane and maintains the structural integrity and intrinsic homing activity of sEVs. GALA-chol TFA can be used in studies related to adjuvant delivery .
Cat. No.: HY-W040144
CAS No.: 76-60-8
Cat. No.: HY-P99899
CAS No.: 2052591-32-7
Synonyms: PR-1498487
Target:
Research Areas:
Cat. No.: HY-129108
CAS No.: 205252-57-9
Synonyms: (9Z)-UAB-30
Research Areas:
9-cis-UAB30 is a rexinoid agonist. 9-cis-UAB30 significantly decreases the proliferation, viability, and motility of both patient-derived xenografts (PDXs). 9-cis-UAB30 induced cell-cycle arrest as demonstrated by the significant increase in the percentage of cells in G1 and a decrease in the percentage of cells in S phase by downregulating SKP2 and/or 20S proteasome activity, which leads to increased p27kip1 protein stability. 9-cis-UAB30 downregulates the abundance of stem cell marker mRNAs (Oct4, Nanog, Sox2, nestin) and upregulates the abundance of differentiation marker mRNAs (β3-tubulin, NSE, HOXC9, GAP43). 9-cis-UAB30 has no adverse effects on the central nervous system and cardiovascular system at the tested dose. 9-cis-UAB30 can be used for the study of neuroblastoma, cutaneous T-cell lymphomas, and breast cancer .
Cat. No.: HY-N0565BR
CAS No.: 24390-14-5
Synonyms: Doxycycline hydrochloride hemiethanolate hemihydrate (Standard); WC2031 (Standard)
Research Areas:
Infection Neurological Disease Inflammation/Immunology Cancer
Doxycycline hyclate (Standard) is the analytical standard of Doxycycline hyclate (HY-N0565B). This product is intended for research and analytical applications. Doxycycline hyclate is an orally active highly lipophilic, tissue-permeable MMP inhibitor with broad-spectrum antibacterial activity. Doxycycline hyclate is also a semi-synthetic antibiotic with chelating properties, which blocks bacterial protein synthesis and inhibits extracellular matrix degradation through interactions with zinc and calcium atoms. Doxycycline hyclate also inhibits mitochondrial biogenesis, translation, and the expression of respiratory chain proteins. Doxycycline hyclate induces apoptosis, inhibits autophagy and EMT, downregulates stem cell markers, and activates the PI3K-AKT pathway, thereby effectively inhibiting the viability and proliferation of cancer cells such as breast cancer cells. Doxycycline hyclate also promotes the survival and self-renewal of embryonic stem cells and neural stem cells, and reduces the frequency of medium changes in culture. Doxycycline hyclate has been applied in studies related to breast cancer, prostate cancer, bladder cancer, and other cancers .
Cat. No.: HY-N0565S1
Cat. No.: HY-16900G
CAS No.: 61413-54-5
Target:
Research Areas:
JO146 is an anti-chlamydial agent, Antibacterial agent, and CtHtrA serine protease inhibitor, with an IC50 of 21.86 μM against CtHtrA serine protease. JO146 alters the morphology of chlamydial cells, reduces inclusion vacuoles, decreases the number of infectious progeny, and eliminates viable Chlamydia trachomatis under stress or conditions that reverse persistent infection. JO146 shows no activity against Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus, but exhibits bactericidal activity against Helicobacter pylori. JO146 can be used in research related to Chlamydia trachomatis infection, chlamydial infection in cattle and sheep, and Helicobacter pylori infection .
Cat. No.: HY-164979
CAS No.: 3051552-64-5
KIF18A-IN-15 (Compound Example 36) is a KIF18A inhibitor, available in two forms, EX36-A and its enantiomer EX36-B, with IC50s of 0.01-0.1 μM, respectively. EX36-A and EX36-B inhibit OVCAR-3 cells viability with IC50s of 0.01-0.1 μM and 0-0.01 μM, respectively. KIF18A-IN-15 can be used in tumor (e.g. colon, breast, lung) studies .
Cat. No.: HY-173047
CAS No.: 2768868-14-8
KRASG12C IN-15 (Compound 21) is the orally active inhibitor for KRAS G12C, and inhibits SOS1-mediated GDP/GTP exchange with an IC50 of 19 nM. KRASG12C IN-15 inhibits the phosphorylation of ERK with IC50 of 0.051 μM. KRASG12C IN-15 inhibits the cell viability of KRAS G12C mutated MIA PaCa-2 with IC50 of 0.023 μM. KRASG12C IN-15 exhibits antitumor effect in MIA PaCa-2 xenograft mouse models .
Cat. No.: HY-173256
Research Areas:
Hyp-dBET1 is a hypoxia-activated BRD4 PROTAC degrader. The IC50 of Hyp-dBET1 for reducing cell viability under hypoxic conditions is approximately 153 nM to 192 nM, while it shows low activity under normoxic conditions (IC50 of approximately 2.8 μM to 3.8 μM). Hyp-dBET1 induces BRD4 degradation under hypoxic conditions, converts to dBET1 in hypoxic environments, and downregulates the expression level of ZFP-91. Hyp-dBET1 can be used in studies related to breast cancer, cervical cancer and solid tumors .
Cat. No.: HY-175271
Target:
Research Areas:
JWJ-01-378 is a TPM3-TRKA fusion protein inhibitor and a wild-type TRK PROTAC degrader. JWJ-01-378 induces degradation via the ubiquitin-proteasome system, and does not degrade TRK inhibitor-resistant mutants or ALK fusion proteins. JWJ-01-378 inhibits downstream signaling pathways activated by TPM3-TRKA fusion, and reduces the viability of cancer cells harboring TPM3-TRKA fusion. JWJ-01-378 can be used to evaluate targeted degradation of TRK fusion proteins in cancer .
Cat. No.: HY-185102
Target:
Research Areas:
ZBP1 PROTAC-1 is a PROTAC degrader targeting ZBP1, with a DC50 of 81.52 nM. ZBP1 PROTAC-1 uses a DNA aptamer to specifically bind ZBP1, recruits the VHL E3 ubiquitin ligase, and induces ZBP1 degradation via the ubiquitin-proteasome pathway. ZBP1 PROTAC-1 can partially restore the viability of H1N1-infected cells. ZBP1 PROTAC-1 can be used in studies related to viral pneumonia and influenza A H1N1 virus infection .
Cat. No.: HY-A0287S
CAS No.: 1346606-66-3
Synonyms: Clomifene-d5 hydrochloride; (Z/E)-Enclomiphene-d5 hydrochloride; (Z/E)-Enclomifene-d5 hydrochloride
Cat. No.: HY-W014684R
CAS No.: 80-54-6
Research Areas:
Lilial (Standard) is the analytical standard of Lilial. This product is intended for research and analytical applications. Lilial is a widely used synthetic fragrance and ester in consumer products. Lilial possesses estrogenic activity in vitro. Lilial can induce a toxic effect on mitochondria that causes a decrease in the viability of HaCaT cells. Lilial can increase NRF2 protein level in vitro. Lilial is able to target respiratory chain complexes, inhibit complexes I and II of the electron transport chain, increase the generation of reactive oxygen species, and decrease the level of intracellular ATP. Lilial can induce systemic toxicity in vivo. Lilial induces significant DNA strand breaks .
Cat. No.: HY-111152R
CAS No.: 912798-42-6
Target:
Research Areas:
ML115 (Standard) is the analytical standard of ML115 (HY-111152). This product is intended for research and analytical applications. ML115, a molecular probe of the signal transducer, is a selective STAT3 agonist, with an EC50 of 2 nM. ML115 increases the expression of BCL3, a known STAT3-dependent oncogene. ML115 is inactive against the related STAT1, STAT5 and NF-κB anti-targets. ML115 counteracts the effects of Ginsenoside Rc (HY-N0042) on cell viability and inflammatory responses in LPS (HY-D1056)-stimulated H9c2 and RAW264.7 cells, while altering oxidative stress markers. ML115 can be used for the study of breast and prostate cancers .
Research Areas:
PROTAC α-synuclein degrader 5 is a selective PROTAC degrader targeting α‑synuclein aggregates, with a DC50 of 7.51 μM. PROTAC α-synuclein degrader 5 binds to αSyn aggregates, recruits the CRBN E3 ubiquitin ligase, and mediates the ubiquitination and subsequent degradation of α‑synuclein aggregates. PROTAC α-synuclein degrader 5 activates the autophagy-lysosome pathway. PROTAC α-synuclein degrader 5 reduces ROS levels in neuroblastoma cells, restores mitochondrial membrane potential, rescues cell viability, and decreases LDH release. PROTAC α-synuclein degrader 5 degrades αSyn aggregates in Caenorhabditis elegans and ameliorates oxidative stress. PROTAC α-synuclein degrader 5 is used for the research of synucleinopathies, such as Parkinson's disease .
Cat. No.: HY-162802
PI3K/AKT-IN-4 (compound 3) is a diterpenoid that can be isolated from the roots and rhizomes of Salvia castanea Dielsf. PI3K/AKT-IN-4 has antitumor activity, inhibiting cell viability and proliferation (IC50=4.72 μM) and promoting apoptosis by blocking the G0/G1 phase of the Hep3B cell cycle, inducing mitochondrial dysfunction and oxidative stress. In addition, PI3K/AKT-IN-4 inhibits hepatocellular carcinoma by inhibiting the PI3K-Akt signaling pathway and binding to PARP1 and CDK2 targets .
Cat. No.: HY-172586
CAS No.: 1574354-24-7
Research Areas:
GSK-3α/β-IN-1 is GSK-3α/β inhibitor with IC50 s of 0.265 μM and 0.255 μM for GSK-3α and GSK-3β, respectively. GSK-3α/β-IN-1 also inhibits PKA with an IC50 of 0.188 μM. GSK-3α/β-IN-1 potently inhibits cell viability of three Glioblastoma (GBM) cell lines (IC50 : 3-6 μM, 72 h) with no toxicity to human astrocytes and good metabolic stability. GSK-3α/β-IN-1 has potential CNS activity in all-human blood-brain barrier (BBB) model of GBM .
Cat. No.: HY-182067
Research Areas:
anti-TNBC agent-15 is a platinum (IV) complex with anti-triple-negative breast cancer activity. anti-TNBC agent-15 inhibits cancer cell viability. anti-TNBC agent-15 reverses the resistance of triple-negative breast cancer cells to Cisplatin (HY-17394), increases intracellular uptake, and effectively triggers apoptosis by inducing DNA damage, enhancing intracellular ROS accumulation and activating the mitochondrial pathway. anti-TNBC agent-15 enhances lipid peroxidation, interferes with the signal transduction of the cystine/glutamate transporter-glutathione peroxidase axis, and induces ferroptosis. anti-TNBC agent-15 significantly inhibits tumor growth in triple-negative breast cancer/Cisplatin xenograft models. anti-TNBC agent-15 can be used for the research of triple-negative breast cancer .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
